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The proto-oncogene RAS, coding for a 21kDa protein (p21), is mutated in 20% of lung cancer. However, the literature remains
controversial on its prognostic significance for survival in lung cancer. We performed a systematic review of the literature with meta-
analysis to assess its possible prognostic value on survival. Published studies on lung cancer assessing prognostic value of RAS mutation
or p21 overexpression on survival were identified by an electronic search. After a methodological assessment, we estimated
individual hazard ratios (HR) estimating RAS protein alteration or RAS mutation effect on survival and combined them using meta-
analytic methods. In total, 53 studies were found eligible, with 10 concerning the same cohorts of patients. Among the 43 remaining
studies, the revelation method was immunohistochemistry (IHC) in nine and polymerase chain reaction (PCR) in 34. Results in terms
of survival were significantly pejorative, significantly favourable, not significant and not conclusive in 9, 1, 31, 2, respectively. In total, 29
studies were evaluable for meta-analysis but we aggregated only the 28 dealing with non-small-cell lung cancer (NSCLC) and not the
only one dealing with small-cell-lung cancer (SCLC). The quality scores were not statistically significantly different between studies
with or without significant results in terms of survival, allowing us to perform a quantitative aggregation. The combined HR was 1.35
(95% CI: 1.16–1.56), showing a worse survival for NSCLC with KRAS2 mutations or p21 overexpression and, particularly, in
adenocarcinomas (ADC) (HR 1.59; 95% CI 1.26–2.02) and in studies using PCR (HR 1.40; 95% CI 1.18–1.65) but not in studies
using IHC (HR 1.08; 95% CI 0.86–1.34). RAS appears to be a pejorative prognostic factor in terms of survival in NSCLC globally, in
ADC and when it is studied by PCR.
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Lung cancer is a major cause of death despite diagnostic and
therapeutic improvements. The overall 5-year survival rate is less
than 10%. However, the prognosis can be modulated by
characteristics related to the patient or to the tumour. Some
independent prognostic factors for survival have already been
identified. They include, for small-cell lung cancer (SCLC): disease
extent and performance status (PS) (Paesmans et al, 2000); for
non-small cell lung cancer (NSCLC): PS, stage and, with lower
impact, age, sex and weight loss (Paesmans et al, 1995; Strauss,
1997).
With the recent progresses in molecular biology, the research on
prognostic factors could be extended to proteins and genes
involved in cancer development. The biological factors implicated
in carcinogenesis should also be considered as potential survival
prognostic factors. Some of them, like angiogenesis and factors
reflecting proliferative state, have already been identified in
patients with lung cancer (Kanters et al, 1995). In order to clarify
the prognostic impact of other biological factors in lung cancer,
our group has performed systematic reviews of the literature with
meta-analyses. It allowed us to show that VEGF (Delmotte et al,
2002), microvessel density (Meert et al, 2002b), c-erbB-2 (Meert
et al, 2003) and p53 (Steels et al, 2001) have statistically significant
worse impact on survival, while Bcl-2 (Martin et al, 2003) has a
favourable survival impact.
Oncogenes (RAS, Raf, Myc, Src, Abl/Bcr, c-erbB-2, y) are
derived from normal genes (the proto-oncogene) coding for
proteins, which play key roles in physiological cellular processes
such as regulations of gene expression or growth signal transduc-
tion. Particularly, RAS oncogene is involved in lung cancer
development. Three human RAS genes (Rodenhuis and Slebos,
1990) have been identified: the HRAS gene (homologous to the
oncogene of the Harvey rat sarcoma virus), the KRAS2 gene
(homologous to the oncogene of the Kirsten rat sarcoma virus) and
the NRAS gene (first isolated from a human neuroblastoma).
These genes code for four highly homologous 21kDa proteins
called p21, with a common effector domain within the N-terminal
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sregion. To be biologically active, RAS proteins must be localised to
the inner face of the plasma membrane, where they can effectively
interact with their upstream activators and downstream targets.
The RAS gene proteins can exist in two states: an active state, in
which GTP is bound to the molecule and an inactive state, in which
the GTP has been hydrolysed to GDP. In physiologic conditions,
the active isoform initiates cell proliferation through the RAS-
dependent kinase cascade. The RAS proteins possess intrinsic
GTPase activity, which normally leads to their inactivation and the
control of cell growth. In tumours, a point mutation resulting in
loss of the intrinsic GTPase activity appears to be associated with
transforming activity of the protein, which does not stop anymore
to send the signal stimulating cell proliferation. KRAS2 mutations
are particularly common in pancreatic cancers, colorectal malig-
nancies and lung cancer (Rodenhuis, 1992; Minamoto et al, 2000).
RAS mutations are detected in 15–20% of NSCLC and,
particularly, 30–50% of adenocarcinomas (ADC) (Rodenhuis
et al, 1988). In lung cancer, 90% of the mutations are located in
the RAS2 gene and both NRAS mutations and HRAS mutations
have occasionally been documented (Rodenhuis and Slebos, 1990).
In total, 80% of KRAS2 mutations occur in codon 12. Other
mutations are located in codons 13 and 61. The predominant
mutation is a G–T transversion (70% of tumours) (Rodenhuis and
Slebos, 1990).
The literature remains controversed on the prognostic value of
RAS for survival in patients with lung cancer. In order to clarify
this question, we have performed a systematic review of the
literature with methodological assessment and meta-analysis.
MATERIALS AND METHODS
Publications selection
To be eligible for the systematic review, a study had to fulfil the
following criteria: to deal only with lung cancer (any stage or
histology), to assess the correlation between RAS mutation or p21
expression and survival, to analyse RAS-p21 in the primary
tumour (not in metastatic tissue or tissue adjacent to the tumour)
and/or antibodies against p21 in the serum, to have been published
as a full paper in the English or French language. Abstracts were
excluded because they do not provide sufficient data to evaluate
the methodological quality of the trial and/or to perform meta-
analysis.
Studies were identified by an electronic search on Medline
databank and using the following keywords: ‘lung cancer’, ‘lung
carcinoma’, ‘lung neoplasms’, ‘lung tumour’, ‘lung tumours’, ‘lung
tumour’, ‘lung tumours’, ‘lung adenocarcinoma’, ‘lung squamous’,
‘NSCLC’, ‘non-small cell lung cancer’, ‘non small cell lung cancer’,
‘non-small cell lung carcinoma’, ‘non small cell lung carcinoma’,
‘SCLC’, ‘small cell lung cancer’, ‘small cell lung carcinoma’, ‘ras’,
‘K-ras’, ‘Ki-ras’, ‘n-ras’, ‘c-ras’, ‘l-ras’, ‘h-ras’, ‘p21’. The search
ended on July 2003. The bibliographies reported in all the
identified studies were used to complete this search. When the
authors reported results obviously obtained on the same patients
population in several publications, only the most recent or the
most complete study was included in the analysis, in order to avoid
overlapping between cohorts.
Methodological assessment
To assess the quality of the methodology, each study was read
independently by 12 investigators, including nine physicians and
three scientists. The participation of many readers was a guarantee
for the correct interpretation of the articles. The methodological
evaluation was scored according to the European Lung Cancer
Working Party (ELCWP) scale. The scoring system used has
already been described in one of our prior systematic reviews
(Steels et al, 2001). Each item was assessed using an ordinal scale
(possible values: 2, 1, 0). A consensus was reached in regular
meetings where at least two-thirds of the investigators needed to be
present. As the assessed items were objective ones, a consensus
was always obtained.
The overall score evaluated several dimensions of the metho-
dology, grouped into four main categories: the scientific design,
the description of laboratory methods used to identify the presence
of RAS mutation or p21 expression, the generalisability of the
results and the analysis of the study data. Each category had a
maximum score of 10 points, with a maximal theoretical score of
40 points. When an item was not applicable to a study, its value
was not taken into account in the total of the concerned category.
The final scores were expressed as percentages, ranging from 0 to
100%, higher values reflecting better methodological quality.
Studies included in the systematic review were called ‘eligible’,
those providing sufficient data for the meta-analysis ‘evaluable’. To
be eligible, studies had to provide univariate analysis.
Statistical methods
A study was considered as significant if the P-value for the
statistical test comparing survival distributions between the groups
with and without RAS-p21 alteration was o0.05. A study was
called ‘positive’ when a mutation/expression in RAS-p21 proto-
oncogene was identified as a significant favourable prognostic
factor for survival. The study was called ‘negative’ if the same
characteristic was associated with a significant detrimental impact
on survival. Finally, a study was called ‘not significant’ if no
statistically significant difference between the two groups was
detected and ‘not conclusive’ if any conclusion about significance
of survival results could be derived from the article.
The association between two continuous variables was measured
by the Spearman rank correlation coefficient. Nonparametric tests
were used to compare the distribution of the quality scores
according to the value of a discrete variable (Mann–Whitney tests
for dichotomic variables or Kruskal–Wallis tests for multiple
classes variables).
For the quantitative aggregation of the survival results, we
measured the impact of RAS mutation and/or p21 expression on
survival by hazard ratio (HR) between the two survival distribu-
tions. For each trial, this HR was estimated by a method depending
on the data provided in the publication. The most accurate method
consisted of calculating the estimated HR and its standard error
(s.e.) from the reported results or to calculate them directly using
two of the following parameters: the O-E statistic (difference
between numbers of observed and expected events), the confidence
interval (CI) for the HR, the logrank statistic or its P-value. If these
were not available, the total number of events, the number of
patients at risk in each group and the logrank statistic or its P-
value were used to allow for an approximation of the HR estimate.
Finally, if the only exploitable data were in form of graphical
representations of the survival distributions, survival rates at some
specified times were extracted in order to reconstruct the HR
estimate and its variance, with the assumption that the rate of
patients censored was constant during the study follow-up
(Parmar et al, 1998). If this last method was used, three
independent persons read the curves to reduce inaccuracy in the
extracted survival rates. The individual HR estimates were
combined into an overall HR using Peto’s method (Yusuf et al,
1985), which consisted of using a fixed effect model assuming
homogeneity of the individual true HRs. This assumption was
tested by performing w
2 tests for heterogeneity. If the assumption
of homogeneity had to be rejected, we used a random-effect model
as a second analysis. By convention, an observed HRo1 implied a
better survival for the group with mutated RAS or p21 expression.
This impact of RAS on survival was considered as statistically
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overlap 1.
When data about global survival of the entire patients
population were available, survival was analysed globally. If
authors only reported the results separately for different sub-
groups, those results corresponded to different cohorts of patients
and were treated separately in the meta-analysis.
RESULTS
Study selection and characteristics
In total, 53 publications, published between 1990 and 2003, were
found eligible for the systematic review (Rodenhuis et al, 1988,
1997; Slebos et al, 1990; Mitsudomi et al, 1991; Miyamoto et al,
1991; Harada et al, 1992; Sugio et al, 1992; Rosell et al, 1993, 1995b,
1996, 1997; Volm et al, 1993, 2002; Westra et al, 1993; Kern et al,
1994; Li et al, 1994; Silini et al, 1994; Fujino et al, 1995; Kashii et al,
1995; Keohavong et al, 1996, 1997; Cho et al, 1997; Dosaka-Akita
et al, 1997; Fukuyama et al, 1997; Komiya et al, 1997; Pifarre ´ et al,
1997; Siegfried et al, 1997; Visscher et al, 1997; De Gregorio et al,
1998; Greatens et al, 1998; Huang et al, 1998; Kim et al, 1998;
Kwiatkowski et al, 1998; Nemunaitis et al, 1998; Wang et al, 1998;
Dingemans et al, 1999; Fu et al, 1999; Graziano et al, 1999; Miyake
et al, 1999; Nelson et al, 1999; Hommura et al, 2000; Konishi et al,
2000; Moldvay et al, 2000; Schneider et al, 2000; Andjelic et al,
2001; Kang et al, 2001; Schiller et al, 2001; Ahrendt et al, 2002;
Broermann et al, 2002; Shoji et al, 2002; Tomizawa et al, 2002;
Grossi et al, 2003; Ramirez et al, 2003). In all, 10 of these articles
were excluded because an identical patient cohort had been used in
other selected publications (Rodenhuis et al, 1988; Miyamoto et al,
1991; Fujino et al, 1995; Rosell et al, 1995a,b, 1996; Dosaka et al,
1997; Keohavong et al, 1997; Hommura et al, 2000; Konishi et al,
2000; Volm et al, 2002). One of the 43 remaining studies (Volm
et al, 1993) assessed separately by immunohistochemistry (IHC)
KRAS2, NRAS and HRAS p21. All the other papers concerned
KRAS2 only. Therefore, for the meta-analysis, we took into
account only the characteristics and the data concerning KRAS2
p21 expression.
The total number of included patients was 5216, ranging from 21
to 355 patients per study (median: 103). The main characteristics
of the 43 publications eligible for the systematic review are
reported in Table 1. In total, 27 were dealing with NSCLC, 11 with
adenocarcinoma only, three with any histological type, one with
SCLC and one with both ADC and large cell carcinoma. A total of
22 studies concerned only nonmetastatic disease, one only stage IV
disease and 19 all stages (I–IV). One study did not mention the
stage of the tumours. In 15 publications, patients were treated by
surgery alone. Surgery was associated with an adjuvant therapy
(radiotherapy and/or chemotherapy) in 26. In one study, SCLC
patients were treated with a combination of radiotherapy and
chemotherapy (Dingemans et al, 1999). In the last paper, treatment
was not described De Gregorio et al, 1998).
Nine studies evaluated the accumulation of p21 protein by
IHC. The other 34 identified RAS mutation by molecular biology,
using different polymerase chain reaction (PCR) methodologies,
mainly, single-strand conformation polymorphism (SSCP)
(n¼10) and restriction fragment length polymorphism (RFLP)
(n¼8).
Among the 43 studies eligible for the systematic review, 14 were
inevaluable for the meta-analysis due to insufficient data reported
in the article. The reasons for noninclusion of a study into the
meta-analysis were the lack of available survival results to calculate
HR in 13 (Volm et al, 1993; Westra et al, 1993; Li et al, 1994; Kashii
et al, 1995; Pifarre ´ et al, 1997; Visscher et al, 1997; De Gregorio
et al, 1998; Greatens et al, 1998; Fu et al, 1999; Miyake et al, 1999;
Schneider et al, 2000; Andjelic et al, 2001; Broermann et al, 2002)
and the lack of repartition of tumours according to RAS mutation/
expression in 1 (Ahrendt et al, 2002).
Study results report
Nine of the 43 studies (20.9%) identified proto-oncogene RAS
mutations or p21 overexpression as a pejorative prognostic factor
for survival (with seven evaluable for the meta-analysis), 31
(72.1%) concluded that RAS was not a prognostic factor for
survival (21 evaluable), one (2.3%) reported a better prognosis for
RAS positivity (evaluable) and two (4.7%) were nonconclusive
(both nonevaluable).
Overall, the rates of RAS mutations detected by PCR and p21
protein overexpression were, respectively, 18.4% (number of
evaluable tumours (n)¼3779) and 44.6% (n¼1548) in NSCLC,
7.1% (n¼141) and 32.3% (n¼223) in squamous cell carcinomas
(SQCC) and 23.1% (n¼1847) and 34.7% (n¼222) in ADC. The
rates of positive tumours by molecular biology or IHC were,
respectively, 21.8% (n¼1015) and 54.8% (n¼135) in stage I
NSCLC, 16.0% (n¼399) and 53.5% (n¼71) in NSCLC patients
with stages I and II, 16.2% (n¼1263) and 38.5% (n¼929) in those
with stages I–III.
Quality assessment
The overall quality score ranged from 31.04 to 78.15% with a
median of 52.2% (Table 2A). The design subscore had the lowest
value, with a median of 40%.
No statistically significant quality difference was shown between
significant and nonsignificant studies neither for the global score
(median: 51.50 vs 53.83%, P¼0.90), neither for the four subgroups
scores. There was also no statistically significant difference
between evaluable and nonevaluable studies for meta-analysis in
terms of global scores (55.23 vs 44.31%, P¼0.10), but the evaluable
ones had a better score concerning the report of the analysis
results: 62.5% in comparison to 31.3% for the nonevaluable trials
(P¼0.001). There was a significant correlation between the global
score and the number of patients included (Spearman correlation
coefficient r¼0.50, P¼0.0006), studies including a higher number
of patients showing a better global score. The generalisability of
the results was significantly better in the recent publications
(r¼0.42, P¼0.004). There was also a statistically significant
difference between studies assessing RAS-p21 status by IHC
(n¼9) or by molecular biology (n¼34), with global scores of
58.51 and 49.93%, respectively (P¼0.029) and scores assessing the
description of the laboratory methodology of 64.3 vs 46%, those
based on IHC being better described than those on molecular
biology (P¼0.002).
Table 2B reports the analysis of the scores for the 29 studies
evaluable for meta-analysis. Their overall quality score ranged
between 34.25 and 78.15%, with a median of 55.24%. The design
subscore was also the worst reported. Like previously observed
among eligible publications, there was no statistically significant
difference between significant and nonsignificant studies evaluable
for the meta-analysis according to the global score (median of
53.04 vs 53.42%, P¼0.92). There was also a significant correlation
between global score and the number of patients included in the
study (Spearman correlation coefficient r¼0.53, P¼0.006) and
those assessing RAS positivity by IHC obtained a better quality
scores for the laboratory method subgroup (57.1 vs 50% for
molecular biology, P¼0.04), but not for the global score.
Meta-analysis
The absence of significant methodological quality difference
between significant and nonsignificant studies allowed us to
perform a quantitative aggregation of the survival results. The
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smeta-analysis was performed on 28 studies (3620 patients) dealing
with NSCLC.
The individual HR of the 28 aggregable studies were calculated
by one of the three methods reported in the Materials and Methods
section according to the available data. Only six studies reported
the data needed to directly calculate the estimated HR (HRs and
95% confidence intervals). In 10 trials, HR was approximated by
the total number of events and the logrank statistic. For the 12
remaining studies, HR had to be extrapolated from the graphical
representation of the survival distributions.
The NSCLC overall meta-analysis included the 28 aggregable
studies with a total number of 3620 patients. Two trials (Fukuyama
et al, 1997; Moldvay et al, 2000) gave only subgroup survival
analysis and their data were analysed separately like reported by
authors, increasing the number of individual cohorts aggregated to
30. The aggregation of the survival data is described in Table 3.
Overall RAS mutation or p21 expression was associated with a
worse survival (HR (fixed effect model) 1.30; 95% confidence
intervals (CI) 1.20–1.49). The test of heterogeneity was significant
(P¼0.01). Nevertheless, we calculated the HR by a random effect
model that showed also a statistically significant impact on
survival with an HR of 1.35 (95% CI: 1.16–1.56).
In the subgroup analysis (Table 3) according to histology, RAS/
p21 was not a statistically significant prognostic factor for survival
in SQCC (H: 1.49, CI 95%: 0.88–2.52), but well in ADC, with
heterogeneity between the trials (heterogeneity test: P¼0.02) and a
random effect HR of 1.59 (CI 95%: 1.26–2.02). The meta-analysis
of studies into three subgroups according to stages (stage I, stage
I–III and stage I–IV) did not show any statistically significant
impact of RAS on survival. For the last subgroup (stage I–IV)
there were 11 studies with a large heterogeneity (Po0.001) and the
random effect HR was borderline (1.41, 95% CI: 0.99–1.99).
Furthermore, we aggregated the studies separately according to
the method used to detect RAS/p21 alteration (Table 3). The
studies were first divided into two main groups according to the
laboratory method: IHC (Figure 1) or molecular biology (Figure 2),
Table 1 Main characteristics and results of the eligible studies
First author Year Histology Stage N pts Laboratory method HR estimation Survival results
Ahrendt 2002 NSCLC I–IIIA 60 PCR-seq No data NC
Andjelic 2001 NSCLC IIIA 21 PCR-SSCP No data Negative
Broermann 2002 NSCLC III 28 PCR-RFLP No data NS
Cho 1997 NSCLC I–IIIB 58 PCR-SSCP Survival curves Negative
De Gregorio 1998 ADC I–IV 184 PCR No data NS
Dingemans 1999 SCLC ANY 93 IHC Survival curves NS
Fu 1999 NSCLC I–IIIB 158 IHC No data NS
Fukuyama 1997 NSCLC I–IV 159 PCR-RFLP Survival curves Negative
Graziano 1999 NSCLC I–II 213 PCR Log rank NS
Greatens 1998 NSCLC I–IV 101 PCR-SSCP No data NS
Grossi 2003 NSCLC I–IIIA 249 PCR HR NS
Harada 1992 NSCLC I–IV 94 IHC Survival curves Negative
Huang 1998 NSCLC I–IIIB 144 PCR-SSCP Survival curves Negative
Kang 2001 NSCLC I–IIIB 61 IHC HR NS
Kashii 1995 ALL I–IV 97 PCR-SSCP No data NS
Keohavong 1996 NSCLC I–IV 126 PCR-DGGE Log rank NS
Kern 1994 ADC I–IV 44 PCR-ASO HR NS
Kim 1998 NSCLC I–IV 238 IHC HR NS
Komiya 1997 NSCLC I–IIIA 137 IHC Survival curves NS
Kwiatkowski 1998 NSCLC I 244 PCR-RFLP Log rank NS
Li 1994 ADC I–? 41 PCR-dot blot No data NS
Mitsudomi 1991 ALL I–IV 66 PCR-RFLP Log rank NS
Miyake 1999 NSCLC I–IIIB 187 PCR-SSCP No data Negative
Moldvay 2000 NSCLC I–IV 227 IHC Log rank NS
Nelson 1999 NSCLC I–IV 355 PCR-RFLP Survival curves Negative
Nemunaitis 1998 ADC+LC I–IV 103 PCR-RFLP Survival curves NS
Pifarre 1997 NSCLC I–IIIA 64 PCR-SSCP No data NC
Ramirez 2003 NSCLC I–IV 50 PCR Survival curves NS
Rodenhuis 1997 ADC III–IV 62 EPCR Log rank NS
Rosell 1997 NSCLC I 35 PCR-SSCP Log rank NS
Rosell 1993 NSCLC I–IIIA 66 PCR-RFLP Log rank Negative
Schiller 2001 NSCLC II–IIIA 184 PCR-RFLP HR NS
Schneider 2000 NSCLC I–IIIA 103 PCR-SSCP No data NS
Shoji 2002 NSCLC I–IIIA 233 IHC Survival curves Positive
Siegfried 1997 ADC I–IV 181 PCR-DGGE Survival curves NS
Silini 1994 ADC I–IV 109 PCR-DGGE Survival curves NS
Slebos 1990 ADC I–IIIA 69 PCR-ASO Log rank Negative
Sugio 1992 ADC I–IV 115 PCR-dot blot Survival curves NS
Tomizawa 2002 ADC I 110 PCR-seq Log rank NS
Visscher 1997 ADC I–IV 31 PCR-SSCP No data NS
Volm (KRAS2) 1993 NSCLC I–III 206 IHC No data NS
Wang 1998 ALL I–IV 53 PCR-seq HR NS
Westra 1993 ADC I–III 57 PCR-ASO No data NS
N pts¼number of patients; HR¼hazard ratio; NSCLC¼non-small-cell lung cancer; ADC¼adenocarcinoma; SCLC¼small-cell lung carcinoma; LC¼large cell;
NC¼nonconclusive; NS¼nonsignificative; PCR¼polymerase chain reaction; SSCP¼single-strand conformation polymorphism; RFLP¼restriction fragment length
polymorphism; ASO¼allele-specific oligonucleotide hybridisation; DGGE¼denaturating gradient gel electrophoresis; seq¼PCR followed by sequencing of olignucleotide;
EPCR¼mutant-enriched PCR; IHC¼immunohistochemistry; HR estimation¼description of the methods used to estimate the individual HR according the three corresponding
of the three different methods described in the statistics paragraph.
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sTable 2 Results of the methodological assessment of (a) eligible studies by the European Lung Cancer Working Party score and (b) evaluable studies by
the European Lung Cancer Working Party score
Global score (%) Design (%) Laboratory methodology (%) Generalisability (%) Results analysis (%)
(a)
All studies (N¼43) 52.2 40 50 67 50
Date of publication
r Spearman 0.28 0.18 0.26 0.42 0.07
P-value 0.07 0.23 0.09 0.004 0.65
Patient number
r Spearman 0.50 0.47 0.14 0.19 0.47
P-value 0.0006 0.001 0.36 0.22 0.002
Significant (n¼10) 51.50 40 46 62.5 62.5
Nonsignificant (n¼31) 53.83 40 50 66.7 50
P-value 0.9 0.93 0.35 0.39 0.41
Evaluable (n¼29) 55.23 40 50 66.7 62.5
Nonevaluable (n¼14) 44.31 45 46 62.5 31.3
P-value 0.10 0.67 0.66 0.8 0.001
Method of revelation
IHC (n¼9) 58.51 50 64.3 66.7 62.5
Molecular biology (n¼34) 49.93 40 46 62.5 50
P-value 0.029 0.53 0.002 0.1 0.22
PCR subgroups
SSCP (n¼10) 48.69 45 42 66.7 50
RFLP (n¼8) 52.56 50 46 62.5 75
P-value 0.33 0.39 0.71 0.86 0.16
Calculation of HR
HR (n¼6) 62.35 50 50 71 75
Log rank (n¼10) 52.96 40 46.4 70.8 62.5
Survival curve (n¼13) 45.92 40 50 66.7 50
No data (n¼14) 44.31 45 46 62.5 31.3
P-value 0.10 0.62 0.62 0.52 0.001
(b)
Evaluable studies (n¼29) 55.24 40 50 66.7 62.5
Date of publication
r Spearman 0.36 0.27 0.25 0.44 0.12
P-value 0.05 0.17 0.19 0.02 0.54
Number of patient
r spearman 0.52 0.69 0.05 0.34 0.34
P-value 0.004 0.00003 0.80 0.07 0.07
Significant (n¼8) 53.33 40 46 62.5 62.5
Nonsignificant (n¼21) 55.42 40 50 66.7 62.5
P-value 0.92 0.82 0.41 0.44 0.65
Method of revelation
IHC (n¼7) 57.59 50 57 66.7 62.5
Molecular biology (n¼22) 51.46 40 50 62.5 62.5
P-value 0.24 0.52 0.04 0.19 0.69
PCR subgroups
SSCP (n¼3) 53.83 40 42 75 50
RFLP (n¼7) 52.08 50 42 58.3 75
P-value 0.73 0.42 0.82 0.73 0.36
Calculation of HR
HR (n¼6) 62.35 50 50 70.8 75
Log rank (n¼10) 52.96 40 46.4 70.8 62.5
Survival curves (n¼13) 45.92 40 50 66.7 50
P-value 0.18 0.47 0.43 0.30 0.037
r Spearman¼correlation coefficient of Spearman; IHC¼immunohistochemistry; PCR¼polymerase chain reaction; SSCP¼single-strand conformation polymorphism;
RFLP¼restriction fragment length polymorphism; HR¼hazard ratio. The P-values are in bold when the statistical test is significant.
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sincluding the different techniques of PCR. The fixed effect HR were
respectively 1.08 (95% CI: 0.86–1.34) and 1.39 (95% CI: 1.22–1.58)
for IHC and molecular biology. For PCR, there was a statistically
significant heterogeneity (P¼0.03) and the random effect HR was
1.40 (95% CI: 1.18–1.65). Among the studies with PCR based
revelation technique, two methods, PCR-RFLP and PCR-SSCP,
were used in respectively six and three studies. Fixed effect HR of
1.7 (95% CI: 1.31–2.19) and 1.32 (95% CI: 0.72–1.47) were
obtained, respectively, the first one only being statistically
significant.
Finally, we decided to perform an analysis in histological
subgroups separately according to the method of detection. There
were only four studies dealing with SQCC and it was a nonsense to
make more reduced subgroups analysis. We were able to analyse
studies including ADC separating those using IHC from those
applying PCR. Four studies were using IHC only. The HR
(random-effects model, p heterogeneity test¼0.01) was 1.48
(95% CI 0.76–2.87). The HR (fixed-effects model, p heterogeneity
test¼0.1) for 11 studies assessing RAS mutation by PCR in ADC
was 1.50 (95% CI 1.26–1.80) (Figure 3).
DISCUSSION
The present systematic review of the literature with meta-analysis
shows that RAS gene alteration and/or protein p21 overexpression
is a poor prognostic factor for survival of patients with NSCLC in
univariate analysis. In subgroup analysis, the negative prognostic
value of RAS alterations is observed in ADC but not for SQCC and
when PCR is used as revelation method but not when IHC is used.
Our data help so to clarify the message of individual studies,
arguing with the hypothesis that RAS is a prognostic factor for
lung cancer. This still needs to be confirmed in prospective trials
with appropriate multivariate analysis taking into account other
clinical or biological prognostic factors. Another meta-analysis
based on a review of the literature on the role of KRAS2 as
prognostic factor in lung cancer was previously published
(Huncharek et al, 1999). Only eight trials (Slebos et al, 1990; Kern
et al, 1994; Silini et al, 1994; Rosell et al, 1995a; Cho et al, 1997;
Fukuyama et al, 1997; Rodenhuis et al, 1997; Siegfried et al, 1997)
Table 3 Hazard ratio (HR) value for the NSCLC subgroup according to histology, stage and laboratory technique
Nb Patients Fixed effects HR (95% CI) v
2 Heterogeneity test Random effects HR (95% CI)
Overall 28 3620 1.30 (1.20–1.49) P¼0.01 1.35 (1.16–1.56)
Histology Squamous 4 280 1.49 (0.88–2.52) P¼0.48
ADC 15 1436 1.52 (1.30–1.78) P¼0.02 1.59 (1.26–2.02)
Disease stage Stages I 5 562 1.26 (0.94–1.69) P¼0.43
Stages I–III 7 882 1.20 (0.93–1.53) P¼0.42
Stages I–IV 11 1553 1.25 (1.04–1.50) Po0.001 1.41 (0.99–1.99)
Laboratory method IHC 7 989 1.08 (0.86–1.34) P¼0.21
PCR 23 2631 1.39 (1.22–1.58) P¼0.03 1.40 (1.18–1.65)
PCR subgroups RFLP 6 765 1.70 (1.31–2.19) P¼0.53
SSCP 3 361 1.32 (0.72–1.47) P¼0.06
ADC IHC 4 266 1.57 (1.13–2.16) P¼0.01 1.48 (0.76–2.87)
PCR 11 1170 1.50 (1.26–1.80) P¼0.1
Nb¼number of studies; ADC¼adenocarcinomas; IHC¼immunohistochemistry; PCR¼polymerase chain reaction; SSCP¼single-strand conformation polymorphism;
RFLP¼restriction fragment length polymorphism; statistically significant results are in bold.
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Figure 1 Meta-analysis of studies assessing RAS with IHC in NSCLC.
Hazard ratio (HR) and 95% confidence interval (CI) of survival in studies
evaluating RAS-p21 status in NSCLC. HR41 implies a survival disadvan-
tage for the group with p21 expression. The square size is proportional to
the number of patients included in the study. The center of the lozenge
gives the combined HR of the meta-analysis and its extremities the 95%
confidence interval. HR¼1.08; CI 95% 0.86–1.34. Total number of
patients: 989.
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Figure 2 Meta-analysis of studies assessing RAS mutation with PCR in
NSCLC. Hazard ratio (HR) and 95% confidence interval (CI) of survival in
studies evaluating RAS-p21 status in NSCLC. HR41 implies a survival
disadvantage for the group with RAS mutation. The square size is
proportional to the number of patients included in the study. The centre of
the lozenge gives the combined HR of the meta-analysis and its extremities
the 95% confidence interval. HR¼1.40; CI 95% 1.18–1.65. Total number
of patients: 2631.
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swere included because the selection criteria of the studies were
different from ours: the search for studies ended in 1997, only
trials documenting KRAS2 mutation by PCR (and not those with
IHC) were included, other histologies than NSCLC were excluded,
2-year survival rates had to be described. The authors observed
that KRAS2 mutations detected by different PCR variants were
poor prognostic factor for NSCLC. These results support the
validity of ours. No subgroup analyses according to stage or
histology (ADC vs SQCC) were performed, not allowing us to
compare with our results.
RAS gene mutations are involved in oncogenesis of a variety of
human tumours (Rodenhuis and Slebos, 1990). In lung cancer,
Fisher et al (2001) has demonstrated that RAS mutation is
necessary for induction and maintenance of lung cancer. The same
author showed that lung tumours arising in the absence of tumour
suppressor gene remain dependent on mutant KRAS2 for
maintenance of tumour growth and that apoptosis after KRAS2
downregulation does not require p53 or Ink4A/Arf. Those points
suggest that RAS plays a key role in lung carcinogenesis. Moreover,
the present demonstration of its prognostic role in lung suggests
that the detection of RAS alteration would also allow us to stratify
patients with higher risk. It could also determine patients with a
better chance to respond to specific treatment targeting RAS.
To avoid bias due to a more detailed reporting of significant
trials, we decided to perform a methodological assessment of the
publications prior to quantitative aggregation. We have used a
methodology similar to previous systematic reviews reported by
our group about biological prognostic factors in lung cancer
(Steels et al, 2001; Delmotte et al, 2002; Meert et al, 2002a,b;
Martin et al, 2003; Meert et al, 2003). The absence of a statistically
significant difference in quality score between the significant and the
nonsignificant publications allowed us to perform a quantitative
aggregation (meta-analysis) of the results of the individual trials.
However, this approach does not prevent all potential biases. Biases
including publication bias, choice of language, selection of fully
published studies only, method of extrapolation of HR, validity of a
meta-analyses based on systematic review of the literature as
compared with those based on individual data were already
discussed in our previous papers (Steels et al, 2001; Delmotte et al,
2002; Meert et al, 2002a,b; Martin et al, 2003; Meert et al, 2003).
Some eligible trials had to be excluded from the meta-analysis
because they did not provide sufficient data on survival. Among
the 14 excluded studies, 12 were nonsignificant (86%) while a
lower proportion of the studies evaluable for the meta-analysis
were nonsignificant (70%). It is known that negative studies are
less frequently published or, if they are, with less detailed results,
making them less assessable. However, the methodological quality
of trials, according to the global score, was not significantly
different between evaluable and nonevaluable studies for the
quantitative aggregation of individual survival results.
Some results need comments: we only demonstrated significant
impact of RAS alterations in ADC and not in SQCC. This
observation suggests that the biological signalling pathways
implicated in carcinogenesis are different for ADC and for SQCC.
Those information should interpreted carefully because RAS
mutations are more frequently observed in ADC as compared
with SQCC (23.12 vs 7.09%) Moreover, authors more often
assessed ADC rather than SQCC (1436 vs 280 patients in the
meta-analysis). For example, Nelson’s trial (Nelson et al, 1999),
firstly based on all histological subtypes, did not detect any
mutation in squamous cell carcinoma and thus did not report data
on this histological subtype. Another example arises in Moldvay‘s
study (Moldvay et al, 2000): she assessed overexpression of p21 by
IHC in all tumours but only evaluate RAS mutation by PCR in
ADC and not in SQCC. There is a potential bias to evalue the
impact of RAS in squamous cell carcinomas and this should be
further investigated.
The diversity in the techniques used to identify alteration of
RAS-p21 status can also be a potential source of bias. Firstly, IHC
is not comparable among the nine studies. There were six different
primary antibodies, different revelation protocols and different
level of positivity (from 0 to 50% or only based on intensity).
Secondly, there is not a good correlation between DNA mutation
and protein conformation or level of protein expression and thus
between molecular biology and IHC. Authors (Nelson et al, 1999;
Moldvay et al, 2000) who studied RAS mutation and p21
expression on the same tumours did not find any correlation
between the two abnormalities. Particularly, Nelson (Nelson et al,
1999) did not observe significant impact of p21 expression in
multivariate analysis (P¼0.89), but well for RAS mutation
(P¼0.04). Moldvay (Moldvay et al, 2000) only found three
patients among 81 analysed with both RAS IHC staining and
KRAS2 point mutation. It could bring some potential explanations
to the difference between IHC and PCR in our meta-analysis. PCR
seems to be a more accurate technique to assess RAS in lung
tumours. It is interesting to observe that we previously had never
showed differences between the two techniques for other markers
like p53 (Steels et al, 2001). This suggests the importance to
determine the best method to assess each marker. There was also a
difference between RFLP- and SSCP-PCR, only the first one
showing statistically significant impact on survival of patient with
lung cancer. There were only three trials with SSCP-PCR and the
results reached to be significant. There is thus need to confirm or
infirm those results prospectively with an adequately designed and
powered trial. The PCR techniques used were thus different
between the trials and between the specific KRAS2 codon analysed.
Whatever, in the other meta-analysis (Huncharek et al, 1999),
pooling all trials with PCR with an heterogeneity detected
according to different procedure and codon analysed, the results
reached significance. For clinical application, the best method to
assess KRAS2 still needs to be determined in further studies to
provide reproductible results and standardised evaluation.
In conclusion, our systematic review suggests that RAS mutation
or p21 expression is of poor prognostic significance for survival in
patients with non-small-cell lung cancer. The results were based on
an aggregation of data obtained by univariate analysis in retro-
spective trials. In order to become a useful prognostic factor at the
level of individual patients and in the context of targeted therapy,
Fukuyama,1999
Huang,1998
Kern,1994
Nelson,1999
Nemunaitis,1998
Rodenhuis,1997
Siegfried,1997
Silini,1994
Slebos,1990
Sugio,1992
Tomizawa, 2002
0.0 2.5 5.0 7.5 10.0
Figure 3 Meta-analysis of studies assessing RAS mutation by PCR in
adenocarcinomas. Hazard ratio (HR) and 95% confidence interval (CI) of
survival in studies evaluating RAS-p21 status in NSCLC. HR41 implies a
survival disadvantage for the group with RAS mutation. The square size is
proportional to the number of patients included in the study. The centre of
the lozenge gives the combined HR of the meta-analysis and its extremities
the 95% confidence interval. HR¼1.50; CI 95% 1.26–1.80. Total number
of patients: 1170.
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sthese results need to be confirmed by an adequately designed
prospective study and the exact value of p21 expression needs to
be determined by an appropriate multivariate analysis taking into
account the classical well-defined prognostic factors for lung
cancer. Moreover, molecular biology arises as a more accurate
technique to assess RAS alteration as compared with IHC. It is a
priority to confirm those data in order to determine the adequate
method to assess RAS, which would then further allow performing
prospective studies with adequate design and, particularly, adapted
laboratory methods.
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